创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

CAO Qingjuan, ZHANG Yaning, LI Tiantian, DU Juanjuan. Reaserch Progress of Pharmacokinetics of Bispecific Antibody[J]. Progress in Pharmaceutical Sciences, 2021, 45(9): 669-684.
Citation: CAO Qingjuan, ZHANG Yaning, LI Tiantian, DU Juanjuan. Reaserch Progress of Pharmacokinetics of Bispecific Antibody[J]. Progress in Pharmaceutical Sciences, 2021, 45(9): 669-684.

Reaserch Progress of Pharmacokinetics of Bispecific Antibody

  • A bispecific antibody (BsAb) is an engineered antibody that simultaneously binds to 2 different epitopes on one or two antigens. Currently, more than 100 bispecific antibodies are under clinical trials with broad therapeutic applications ranging from cancer to autoimmune diseases. Rapid development of biotechnology has generated various formats to construct bispecific antibodies, which exhibit distinct pharmacokinetic (PK) behaviors of absorption, distribution, metabolism and excretion. Therefore, the in-depth study of the PK behaviors is critical for the rational design of bispecific antibodies. This review summarizes the formats and PK performances of the bispecific antibodies currently under clinical trials, aiming to provide reference for the design of bispecific antibody drugs and their clinical trials.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return